MX2011007557A - Formas nuevas de bendamustina como base libre. - Google Patents

Formas nuevas de bendamustina como base libre.

Info

Publication number
MX2011007557A
MX2011007557A MX2011007557A MX2011007557A MX2011007557A MX 2011007557 A MX2011007557 A MX 2011007557A MX 2011007557 A MX2011007557 A MX 2011007557A MX 2011007557 A MX2011007557 A MX 2011007557A MX 2011007557 A MX2011007557 A MX 2011007557A
Authority
MX
Mexico
Prior art keywords
free base
bendamustine free
forms
novel forms
bendamustine
Prior art date
Application number
MX2011007557A
Other languages
English (en)
Inventor
Laurent D Courvoisier
Mark Eddleston
Curtis R Haltiwanger
Robert E Mckean
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011007557(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2011007557A publication Critical patent/MX2011007557A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen formas polimórficas nuevas de la bendamustina como base libre, incluidas la bendamustina como base libre amorfa, seis formas cristalinas anhidras, cuatro formas de hidrato y cinco formas de solvato, y también se describen métodos para su preparación y empleo.
MX2011007557A 2009-01-15 2010-01-14 Formas nuevas de bendamustina como base libre. MX2011007557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14484309P 2009-01-15 2009-01-15
PCT/US2010/020992 WO2010083276A1 (en) 2009-01-15 2010-01-14 Novel forms of bendamustine free base

Publications (1)

Publication Number Publication Date
MX2011007557A true MX2011007557A (es) 2011-08-12

Family

ID=42008533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007557A MX2011007557A (es) 2009-01-15 2010-01-14 Formas nuevas de bendamustina como base libre.

Country Status (16)

Country Link
US (1) US8076366B2 (es)
EP (1) EP2387400A1 (es)
JP (1) JP2012515210A (es)
KR (1) KR20110110293A (es)
CN (2) CN102281877B (es)
AU (2) AU2010204765A1 (es)
BR (1) BRPI1004922A2 (es)
CA (1) CA2749101A1 (es)
EA (1) EA020767B1 (es)
IL (1) IL213725A0 (es)
MX (1) MX2011007557A (es)
NZ (1) NZ594010A (es)
SG (1) SG172810A1 (es)
UA (1) UA109109C2 (es)
WO (1) WO2010083276A1 (es)
ZA (1) ZA201105099B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376394B2 (en) * 2009-12-23 2016-06-28 Dr. Reddy's Laboratories Ltd. Preparation of bendamustine and its salts
PT3158991T (pt) 2010-01-28 2021-06-23 Eagle Pharmaceuticals Inc Formulações de bendamustina
US9273010B2 (en) * 2011-06-20 2016-03-01 Hetero Research Foundation Process for bendamustine hydrochloride
EP2827863B1 (en) 2012-03-20 2019-01-16 Eagle Pharmaceuticals, Inc. Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
CA2867295C (en) 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP3135276B1 (en) 2013-03-12 2019-05-08 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
EP2988655B1 (en) 2013-04-26 2023-04-12 Genentech, Inc. Contour integration perimetry vision test
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159877C (es)
DE293808C (es)
DE159289C (es) 1903-10-08 1905-03-16
DE80967C (es)
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DE69421936T2 (de) 1993-10-27 2000-06-29 Upjohn Co Stabilisiertes prostaglandin e1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
PT1104297E (pt) 1998-07-09 2006-05-31 Cephalon Inc Composicoes para o tratamento da leucemia linfocitica cronica
US5972912A (en) 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
HUP0401811A2 (hu) 2000-12-11 2004-12-28 Takeda Chemical Industries, Ltd. Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására
HUP0400683A2 (hu) 2000-12-11 2004-06-28 Takeda Chemical Industries, Ltd. HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény
DK1435877T3 (da) 2001-10-15 2009-08-03 Hemoteq Ag Overtrækning af stents for at forhindre restenose
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
EP1485720B1 (en) 2002-03-22 2008-03-12 Ludwig Maximilians Universität Cytocapacity test
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
ATE404232T1 (de) 2002-05-09 2008-08-15 Hemoteq Ag Hemokompatibel beschichtete medizinprodukte, deren herstellung und verwendung
US20040096436A1 (en) 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
CA2516191A1 (en) 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
EP1648454A1 (en) 2003-07-25 2006-04-26 Wyeth Cci-779 lyophilized formulations
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN102177140B (zh) * 2008-10-08 2016-01-27 赛福伦公司 用于制备苯达莫司汀的方法

Also Published As

Publication number Publication date
IL213725A0 (en) 2011-07-31
EA020767B1 (ru) 2015-01-30
EA201170934A1 (ru) 2011-12-30
ZA201105099B (en) 2012-03-28
UA109109C2 (uk) 2015-07-27
US20100210701A1 (en) 2010-08-19
BRPI1004922A2 (pt) 2019-09-24
AU2010204765A1 (en) 2011-07-28
JP2012515210A (ja) 2012-07-05
NZ594010A (en) 2013-08-30
SG172810A1 (en) 2011-08-29
CN103554030A (zh) 2014-02-05
KR20110110293A (ko) 2011-10-06
WO2010083276A1 (en) 2010-07-22
AU2016204902A1 (en) 2016-08-04
CN102281877A (zh) 2011-12-14
CN102281877B (zh) 2014-07-23
US8076366B2 (en) 2011-12-13
CA2749101A1 (en) 2010-07-22
EP2387400A1 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
MX2011007557A (es) Formas nuevas de bendamustina como base libre.
HK1222853A1 (zh) 氘化苯並喹啉衍生物作為囊泡單胺轉運 的抑制劑
HRP20150477T1 (en) Methods of preparing quinazolinone derivatives
SG10201407927UA (en) Imidazopyridine derivatives as jak inhibitors
LT2247582T (lt) Dimetoksidocetakselio bevandenė kristalinė forma
MX342913B (es) Formas solidas de romidepsina y sus usos.
JO2887B1 (en) Spiro-pyridine compounds as ORL-1 receptor antagonists
EP2571548A4 (en) COMPRESSIBLE TUBES FOR POSITIONING IMPLANTS, RELATED MEDICAL KITS AND METHODS OF USE THEREOF
ZA201301992B (en) High toughness thermally stable polycrystalline diamond
MX2015003124A (es) Formas polimorficas de enzalutamida y su preparacion.
EP2486039A4 (en) HSP90 INHIBITORS SUITABLE PURE DERIVATIVES
EP2635558A4 (en) PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
MY165234A (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
AP3521A (en) Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors
IL214421A0 (en) Methods for producing human amniotic cell lines
WO2011104723A3 (en) Acid addition salts of ivabradine and preparation method thereof
EP2519510A4 (en) PROCESS FOR PRODUCING HIGH-PURITY, WATER-FREE AND CRYSTALLINE DOCETAXEL
EP2523971A4 (en) THERAPEUTIC APYRASE CONSTRUCTS, APYRACE AGENTS AND MANUFACTURING METHOD
ZA201202097B (en) Crystalline forms of substituted pyrazolopyrimidines
EP2594544A4 (en) CERAMIC ELEMENT AND METHOD FOR PRODUCING A PROBE HOLDER AND A CERAMIC ELEMENT
IL216751A0 (en) Methods of generating cells exhibiting phenotypic plasticity
EP2349988A4 (en) ORGANIC NUTRIENT SALTS, PREPARATION METHODS AND USES THEREOF
HUP0900130A2 (en) Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
AU2009902649A0 (en) Methods of generating cells exhibiting phenotypic plasticity
TN2010000377A1 (en) Forms of rifaximin and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration